Literature DB >> 12750098

Survival rates with uveal melanoma in the United States: 1973-1997.

Arun D Singh1, Allan Topham.   

Abstract

PURPOSE: To determine variations in 5-year relative survival rates with primary uveal melanoma in the United States over a 25-year period from 1973 to 1997.
DESIGN: Systematic review of existing databases. PARTICIPANTS: Two thousand four hundred ninety-three patients with primary uveal melanoma, International Classification of Oncology [ICDO-2] codes C69.3 [choroid melanoma] and C69.4 [ciliary body and iris]) derived from Surveillance, Epidemiology, and End Results (SEER) program database in the United States from 1973 to 1997.
METHODS: The patients were stratified according to the treatment (surgery or radiotherapy). The relative 5-year survival was calculated for 2054 patients diagnosed between 1973 and 1993 by the life table method using US life expectancy tables. MAIN OUTCOME MEASURES: The relative 5-year survival rate.
RESULTS: Surgical treatment was performed in 1476 (72%) cases, and radiotherapy was given in 300 (15%) cases. The proportion of cases treated by radiotherapy increased progressively from 2% to 28% in 20 years. Relative 5-year survival rates ranged from 77% to 84% without a statistically significant variation.
CONCLUSIONS: Advances made in the local methods of treatment of primary uveal melanoma have not led to an improvement in survival. Systemic approaches to management of uveal melanoma are warranted.

Entities:  

Mesh:

Year:  2003        PMID: 12750098     DOI: 10.1016/S0161-6420(03)00077-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  64 in total

Review 1.  The Zimmerman-McLean-Foster hypothesis: 25 years later.

Authors:  A D Singh; I G Rennie; T Kivela; S Seregard; H Grossniklaus
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

2.  Integrative Copy Number Analysis of Uveal Melanoma Reveals Novel Candidate Genes Involved in Tumorigenesis Including a Tumor Suppressor Role for PHF10/BAF45a.

Authors:  Hima Anbunathan; Ruth Verstraten; Arun D Singh; J William Harbour; Anne M Bowcock
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

3.  Frequency, molecular pathology and potential clinical significance of partial chromosome 3 aberrations in uveal melanoma.

Authors:  Mohamed H Abdel-Rahman; Benjamin N Christopher; Mohammed F Faramawi; Khaled Said-Ahmed; Carol Cole; Andrew McFaddin; Abhik Ray-Chaudhury; Nyla Heerema; Frederick H Davidorf
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

Review 4.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 5.  Uveal melanoma as a target for immune-therapy.

Authors:  Marc Oliva; Antonio J Rullan; Josep M Piulats
Journal:  Ann Transl Med       Date:  2016-05

6.  Reduced expression of autotaxin predicts survival in uveal melanoma.

Authors:  Arun D Singh; Karen Sisley; Yaomin Xu; Jianbo Li; Pieter Faber; Sarah J Plummer; Hardeep S Mudhar; Ian G Rennie; Patricia M Kessler; Graham Casey; Bryan G Williams
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

7.  Cell growth inhibition in HPV 18 positive uveal melanoma cells by E6/E7 siRNA.

Authors:  Biyun Cun; Xin Song; Renbing Jia; Haibo Wang; Xiaoping Zhao; Bo Liu; Shengfang Ge; Xianqun Fan
Journal:  Tumour Biol       Date:  2013-03-14

8.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

9.  Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.

Authors:  Nabil Amirouchene-Angelozzi; Fariba Nemati; David Gentien; André Nicolas; Amaury Dumont; Guillaume Carita; Jacques Camonis; Laurence Desjardins; Nathalie Cassoux; Sophie Piperno-Neumann; Pascale Mariani; Xavier Sastre; Didier Decaudin; Sergio Roman-Roman
Journal:  Mol Oncol       Date:  2014-06-13       Impact factor: 6.603

10.  PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.

Authors:  Wanhua Yang; Peter W Chen; Haochuan Li; Hassan Alizadeh; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02-22       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.